What patient and health facility attributes predict retention and virologic suppression in private for-profit health centers? A retrospective cohort analysis of data from a large private sector antiretroviral treatment program in Nigeria

Muyi Aina (✉ muyi.solina@gmail.com)  
Solina Center for International Development and Research  
https://orcid.org/0000-0001-9686-7685

Zeena Yesufu  
Solina Center for International Development and Research

Abdulateef Salisu  
Solina Center for International Development and Research

Echezona Ezeanolue  
Solina Center for International Development and Research

Charles Mensah  
Solina Center for International Development and Research

Patrick Dakum  
Solina Center for International Development and Research

Research Article

Keywords: HIV, AIDS, Private Facilities, Implementation Science, Nigeria, Patient Outcomes

Posted Date: September 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-880142/v1

License: ☺ ① This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background
In Nigeria, private for-profit health facilities present an opportunity to achieve the 95-95-95 HIV targets because of their reach and patronage. However, little is known about determinants of outcomes in these facilities. This study describes patient outcomes and their determinants in adults receiving HIV treatment in private facilities in 3 states in north-central Nigeria.

Methods
A retrospective longitudinal analysis of program data collected between 2013 and 2019 was done. Patient attributes and outcomes were compared across states. Incidence rates were determined for all outcomes. Cox proportional hazard models and multivariate logistic regression models were used to identify associations with and predictors of study outcomes respectively.

Results
42.7%, 22.2% and 35.1% of the 22,010 study subjects were in Benue, FCT and Nasarawa respectively. 31.8% had been on ART for less than a year at censoring. Incidence rates for all-cause exit, mortality and LTFU were 17.2, 2.1 and 11.2 per 100 person years respectively. Males had higher risks of death (HR = 1.47), and LTFU (HR = 1.08). Age at ART start showed a dose-response association with both mortality and LTFU. Care at model facilities (OR = 2.16), AZT-based regimens (OR = 2.00), and low baseline CD4 + count (OR = 2.40) were predictors of regimen switch. 75.6% of subjects were viral suppressed. Male gender (OR = 0.84); AZT-based regimen (OR = 0.72), age in the bottom quartile (OR = 0.71) were predictors of viral suppression.

Conclusion
Private sector patient outcomes are comparable to public sector programs. Appropriate technical support and engagement will facilitate combined efforts to achieve epidemic control of HIV in Nigeria.

Introduction
The 2018 Nigerian National AIDS Indicator and Impact Survey (NAIIS), the largest ever population-based HIV impact assessment (PHIA) globally, showed a prevalence of 1.5% among people aged 15–69 years [1]. This represents a remarkable decline in HIV disease burden since the country began using sentinel surveys to track its epidemic. Prior to this, the national prevalence rose from 1.8% in 1991 to a peak of 5.8% in 2001 before declining to 5.0% in 2003 and 2.3% in 2015 [2][3][4][5]. This trend suggests that the massive efforts of the government and its development and donor partners to control the HIV epidemic during the last three decades have achieved results[3][6][7][8][9][10].

With its estimated 1.9 million people living with HIV, Nigeria remains the 4th largest contributor to the global burden of HIV[1]. In 2017, the country accounted solely for more than half of the 260,000 new HIV infections in West and Central Africa, of which 36,000 were in children[11]. It also contributed over half of deaths due to AIDS related illnesses in the region [11]. Nigeria’s HIV epidemic is mixed, with persisting pockets of high prevalence[12]. The national prevalence of 1.5% masks subnational variations that range from 0.3% in Kebbi, Katsina and Jigawa States in the northwest region, to 5.5% in Akwa-Ibom state in the south-south region[1][6]. Only 7 out of the 36 states in the country account for more than 50% of the national HIV burden, and 80% of the combined burden is attributable to only 13 of the 37 states[1][13]. These disparities reflect wide inequities in poverty, education and access to HIV prevention services, as well as geographical differences in high-risk behaviors and harmful socio-cultural practises, stigma and discrimination[2][12][14].

The HIV response in Nigeria is government-led but largely donor-funded, with many programs initially focusing on supporting the public sector’s capacity to provide comprehensive HIV prevention, care and treatment services in secondary and tertiary health facilities [7][8][15][16]. However, coverage of services remained limited by the inadequate number of service delivery points[17]. To bridge the coverage gaps, the government and its partners rolled out a strategy to decentralize ART to primary health centers and implemented a task shifting policy that allowed nurses and allied health workers to be trained and empowered to provide varying levels of services in the HIV prevention, care and treatment continuum [18][19][20]. Currently, Nigeria still falls far short of the UNAIDS 90-90-90 targets set for
2020, with only about 1 million people, approximately 52% of PLHIV, currently on ART [11][21][22]. Despite this huge gap in service coverage, the potential for Nigeria to expand access to HIV services through private providers remains largely under-tapped [20][23]. Up to 65% of all citizens, and 72% of the poorest quintile, access basic health services from private sector outlets [24][25]. As such, private providers can not only help accelerate progress towards the revised 95-95-95 targets by 2030, but also reduce inequities in access to HIV prevention, care and treatment services. There is currently little or no data on performance of private facilities in provision of HIV services in Nigeria.

Solina Center for International Development and Research (SCIDaR), with sub-grant funding from the Institute of Human Virology, Nigeria (IHVN), designed and began implementing a model to support private for-profit facilities to provide HIV prevention, care and treatment services in Nigeria in 2013. This paper presents patient outcomes and predictors of those outcomes in adult patients receiving ART in private health facilities supported by the SCIDaR-IHVN program in Benue and Nasarawa states, and the Federal Capital Territory (FCT), all high burden regions in northcentral Nigeria between 2013 and 2019.

Methods

This study is a retrospective analysis of routinely collected longitudinal data for patients enrolled in the SCIDaR-IHVN private sector HIV care and treatment program in Benue, Nasarawa, and the FCT between January 2013 and November 2019. All adult patients (aged 18 years and above), who received ART for at least one month in any of the 214 private health facilities supported by the program were included in this study. Routinely collected patient-level demographic and clinical data was extracted from the PEPFAR Retention and Audit Determination Tool (RADET) database. The data was cleaned, organized and analyzed using Stata® 13 SE [26].

Data analysis

The outcomes of interest were viral suppression (< 1,000 copies/ml) in most recent viral load test [27], all-cause exit, death, loss to follow up (LTFU)), and regimen switch to 2nd line. Demographic and clinical care characteristics were compared across states using Pearson's chi squared tests of proportions for categorical variables, including gender, pregnancy status, year enrolled in ART, duration on ART (years), starting ART regimen base (Tenofovir, Zidovudine or other), current ART treatment line (1st or 2nd line), ART refill appointment duration (1, 2 and 3 or more months), and host health facility support type (model facilities received more intensive technical assistance than standard support facilities). Means of continuous variables (age at ART start, baseline CD4 + count) were compared across states with one-way ANOVA.

Treating time on ART, in months, at point of exit as the analysis time, overall and state-specific incidence rates with 95% confidence intervals were calculated for all-cause exit, mortality, LTFU, treatment stoppage and transfers out. In addition, state-specific and overall incidence rates of regimen switch from 1st to 2nd line was determined. Cox proportional hazards models were used to identify demographic, clinical and patient care characteristics that were associated with all-cause exit, mortality, and LTFU in the study population. In addition, a logistic regression model was used to identify patient characteristics that were associated with regimen switch to 2nd line.

Viral suppression rates (proportion of patients with most recent viral load < 1,000 c/ml) were calculated for each state and for the overall study population. The state-specific rates were compared using a Pearson chi squared test. Predictors of viral suppression in the study population were determined using multivariate logistic regression models. Patient characteristics assessed for relationship with viral suppression include gender, age at ART start (years, categorized into quartiles), state of residence, pregnancy status, host health facility support type, ART enrolment year, duration on ART in years, months of ARV refill (1 month, 2 months, or ≥ 3 months), baseline CD4 + count (categorized into quartiles), current regimen base, and contact testing status. Adjusted ORs for viral suppression by ART enrolment year and by duration on ART in years from the best fit multivariate logistic regression model were charted to identify any trends over time.

Results

A total of 22,010 patients meeting the inclusion criteria were included in this analysis. This number included 442 patients (2.0%) who had commenced ART prior to joining the program in 2013. As shown in Table 1, 42.7%, 22.2% and 35.1% of study subjects were in Benue, FCT and Nasarawa respectively. Majority (70.9%) were female, with a significantly higher proportion of females in Benue than FCT and Nasarawa. Among the female study subjects, 3.9% were pregnant and 3.6% breastfeeding at time of data recording. Mean age
at start of ART was 33.8 years (SD 9.9 years). Overall, almost 1 in 6 (17.3%) patients commenced ART in 2013 or earlier, with Benue contributing more to this group (19.9%) compared to FCT (12.7%) or Nasarawa (16.9%). Overall annual enrolment increased gradually to peak at 24.0% in 2016, after which enrolment began to decline. As at time of exit from the program or censoring, 31.8% of subjects had been on ART for a year or less and 12.9% had received ART for 4 years or more. Mean baseline CD4 + count was slightly higher for Benue-based patients at 385.2 cells/ml, compared to the overall mean of 374.5 cells/ml. The majority (81.5%) of patients were started on tenofovir (TDF) -based treatment regimens and few (1.0%) had switched to second line regimens as of time of analysis. As table 1 shows, majority of patients in FCT (54.7%) and Nasarawa (52.4%) refilled their medications monthly, while most patients in Benue (50.7%) refilled every two months. Overall contact testing rate was 85.9% on the program. A slightly lower proportion of clients in Benue (78.0%) had their contacts tested. 44.5% of patients in FCT, 33.7% in Nasarawa and none in Benue received their care in health facilities categorized as model sites.
| Table 1. Characteristics of study participants |
|---------------------------------------------|
|                                             |
| **Sex, N (%)**                              |
| Female                                      |
| Benue 6,977 (74.3)                          |
| FCT   3,298 (67.4)                          |
| Nasarawa 5,325 (68.9)                      |
| Combined 15,600 (70.9)                     |
| **p-value**                                 |
| 0.000*                                      |
| Male                                        |
| Benue 2,415 (25.7)                         |
| FCT   1,597 (32.6)                         |
| Nasarawa 2,403 (31.1)                      |
| Combined 6,410 (29.1)                      |
| **Age at ART start, mean (SD)**            |
| Benue 33.8 (10.4)                           |
| FCT   34.3 (9.4)                            |
| Nasarawa 33.5 (9.5)                        |
| Combined 33.8 (9.9)                        |
| **p-value**                                 |
| 0.000**                                     |
| **Pregnancy status†, N (%)**                |
| Not pregnant                                |
| Benue 6,353 (91.1)                          |
| FCT   3,069 (93.1)                          |
| Nasarawa 5,010 (94.1)                      |
| Combined 14,432 (92.5)                     |
| **p-value**                                 |
| 0.000*                                      |
| Pregnant                                    |
| Benue 318 (4.6)                             |
| FCT   116 (3.5)                             |
| Nasarawa 167 (3.1)                         |
| Combined 601 (3.9)                         |
| Breastfeeding                               |
| Benue 306 (4.4)                             |
| FCT   113 (3.4)                             |
| Nasarawa 148 (2.8)                         |
| Combined 567 (3.6)                         |
| **Duration on ART, N (%)**                  |
| 0–1 year                                    |
| Benue 3,452 (36.8)                          |
| FCT   1,562 (31.9)                          |
| Nasarawa 1,993 (35.8)                      |
| Combined 7,007 (31.8)                      |
| **p-value**                                 |
| 0.000*                                      |
| 1–2 years                                   |
| Benue 2,831 (30.1)                          |
| FCT   1,069 (21.9)                          |
| Nasarawa 1,505 (19.5)                      |
| Combined 5,405 (24.6)                      |
| 2–3 years                                   |
| Benue 1,782 (19.0)                          |
| FCT   940 (19.2)                            |
| Nasarawa 1,458 (19.9)                      |
| Combined 4,180 (19.0)                      |
| 3–4 years                                   |
| Benue 882 (9.4)                             |
| FCT   583 (11.9)                            |
| Nasarawa 1,118 (14.5)                      |
| Combined 2,583 (11.7)                      |
| 4 + years                                   |
| Benue 445 (4.5)                             |
| FCT   736 (15.1)                            |
| Nasarawa 1,654 (21.4)                      |
| Combined 2,835 (12.9)                      |
| **Baseline CD4 + count, mean (SD)**         |
| Benue 385.5 (234.3)                         |
| FCT   374.5 (283.2)                         |
| Nasarawa 362.1 (278.0)                     |
| Combined 374.5 (265.2)                     |
| **p-value**                                 |
| 0.000**                                     |
| **ART regimen at start, N (%)**             |
| TDF based                                   |
| Benue 8,020 (85.4)                          |
| FCT   3,634 (74.3)                          |
| Nasarawa 6,289 (81.4)                      |
| Combined 17,943 (81.5)                     |
| **p-value**                                 |
| 0.000*                                      |
| AZT based                                   |
| Benue 1,364 (14.5)                          |
| FCT   1,241 (25.4)                          |
| Nasarawa 1,431 (18.5)                      |
| Combined 4,036 (18.3)                      |
| Other                                       |
| Benue 8 (0.1)                               |
| FCT   15 (0.3)                              |
| Nasarawa 8 (0.1)                            |
| Combined 31 (0.1)                           |
| **Current ART line, N (%)**                 |
| 1st line                                    |
| Benue 9,345 (99.5)                          |
| FCT   4,811 (98.4)                          |
| Nasarawa 7,625 (98.7)                      |
| Combined 21,781 (99.0)                     |
| **p-value**                                 |
| 0.000*                                      |
| 2nd line                                    |
| Benue 47 (0.5)                              |
| FCT   79 (1.6)                              |
| Nasarawa 103 (1.3)                          |
| Combined 229 (1.0)                          |
| ARV refill duration, N (%)                  |
| 1 month                                     |
| Benue 3,489 (37.2)                          |
| FCT   2,674 (54.7)                          |
| Nasarawa 4,049 (52.4)                      |
| Combined 10,212 (46.4)                     |
| **p-value**                                 |
| 0.000*                                      |
| 2 months                                    |
| Benue 4,762 (50.7)                          |
| FCT   1,568 (32.1)                          |
| Nasarawa 2,987 (38.7)                      |
| Combined 9,317 (42.3)                      |
| 3 + months                                  |
| Benue 1,141 (12.2)                          |
| FCT   648 (13.3)                            |
| Nasarawa 692 (9.0)                          |
| Combined 2,481 (11.3)                      |
| Contact tested, N (%)                       |
| No                                           |
| Benue 174 (78.0)                            |
| FCT   3,649 (83.5)                          |
| Nasarawa 6,230 (87.6)                      |
| Combined 10,052 (85.9)                     |
| **p-value**                                 |
| 0.000*                                      |
| Yes                                          |
| Benue 49 (22)                               |
| FCT   719 (16.5)                            |
| Nasarawa 882 (12.4)                         |
| Combined 1,650 (14.1)                      |
| Facility support, N (%)                     |
| Standard                                    |
| Benue 9,392 (100)                           |
| FCT   2,712 (55.5)                          |
| Nasarawa 5,122 (66.3)                      |
| Combined 17,226 (78.3)                     |
| **p-value**                                 |
| 0.000*                                      |
| Model§                                      |
| Benue 0                                     |
| FCT   2,178 (44.5)                          |
| Nasarawa 2,606 (33.7)                      |
| Combined 4,784 (21.7)                      |
### Table 1. Characteristics of study participants

|     | Total       | Female patients only included in analysis. | Benue state ceded out of program to another implementer in 2018. | Model facility support approach introduced in 2018 after sites in Benue had been ceded. | P-value from Pearson's Chi-squared test of proportions. | P-value from Bartlett's test for equal variances. | FCT – Federal Capital Territory |
|-----|-------------|--------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------|----------------------------------|
|     | 9,392 (42.7) | 4,890 (22.2)                               | 7,728 (35.1)                                                     | 22,010 (100)                                                                          | 0.000*                                               |                                                   |                                   |

† Female patients only included in analysis.
‡ Benue state ceded out of program to another implementer in 2018.
§ Model facility support approach introduced in 2018 after sites in Benue had been ceded.
* P-value from Pearson's Chi-squared test of proportions.
** P-value from Bartlett's test for equal variances.

---

**All-cause exit, mortality, loss to follow up (LTFU) and treatment stoppage**

Table 2 shows the crude incidence rates, with 95% CIs, for all-cause exit, mortality, loss to follow up (LTFU) and treatment stoppage in the study. Overall rate for all-cause exit was 17.2 per 100 person years, with Benue recording 11.3 per 100 person years compared to FCT’s 22.6 and Nasarawa’s 18.9 per 100 person years. Also, the program recorded 2.1 deaths, 11.2 losses to follow up, 0.6 treatment stoppages and 3.2 out-transfers per 100 person years combined. Again, rates for all types of exit were lowest in Benue (Table 2).

#### Table 2

| Incidence rates‡ (95% CI) | Benue   | FCT      | Nasarawa | Combined |
|---------------------------|---------|----------|----------|----------|
| **All-cause exit**        | 11.3 (10.8, 11.8) | 22.6 (21.7, 23.5) | 18.9 (18.3, 19.5) | 17.2 (16.8, 17.5) |
| **Mortality**             | 1.8 (1.6, 2.0)   | 2.3 (2.0, 2.6)   | 2.3 (2.1, 2.5)   | 2.1 (2.0, 2.2)   |
| **LTFU**                  | 7.4 (7.0, 7.9)   | 15.2 (14.5, 16.0) | 12.1 (11.6, 12.6) | 11.2 (10.9, 11.5) |
| **Treatment stoppage**    | 0.4 (0.3, 0.5)   | 0.9 (0.7, 1.1)   | 0.7 (0.6, 0.8)   | 0.6 (0.6, 0.7)   |
| **Transferred out**       | 1.7 (1.5, 1.9)   | 4.3 (3.9, 4.7)   | 3.9 (3.6, 4.2)   | 3.2 (3.1, 3.4)   |
| **Regimen switch to 2nd line** | 0.3 (0.2, 0.4) | 0.5 (0.4, 0.7) | 0.5 (0.4, 0.6) | 0.4 (0.4, 0.5) |

† Incidence rates calculated per 100 person years.
FCT – Federal Capital Territory; LTFU – Lost to follow up

Results of multivariate Cox proportional hazard models showing associations of patient attributes with the different types of program exit are shown in Table 3. Overall, males had statistically significant higher risks of all-cause exit (HR 1.10, 95% CI 1.04–1.17), death (HR 1.47, 95% CI 1.25–1.73), and loss to follow up (HR 1.08, 95% CI 1.00–1.16) than females. Risk of all-cause exit was higher among subjects in FCT (HR 2.61, 95% CI 1.87–3.65) and in Nasarawa (HR 1.97, 95% CI 1.41–2.75) than for subjects in Benue. Likewise, subjects receiving care in facilities located in FCT and Nasarawa had significantly higher risks of being lost to follow up than those in Benue. However, there were no statistically significant differences in risk of mortality across states. Breastfeeding was associated with lower risks of all-cause exit (HR 0.64, 95% CI 0.50–0.81) and loss to follow up (HR 0.62, 95% CI 0.46–0.83) compared to adults who are neither pregnant nor breastfeeding. Pregnancy was not significantly associated with risk of program exit in this study. As shown in Table 3, subjects’ age at ART start showed a dose-response association with both mortality (lower age progressively associated with increasing risk of mortality) and loss to follow up (lower age progressively associated with increasing risk of LTFU). Patients who refilled their ART medications had higher risks of all-cause exit (HR 2.21, 95% CI 2.01–2.43), mortality (HR 3.34, 95% CI 2.40–4.62), and LTFU (HR 2.21, 95% CI 1.97–2.47) than those who refilled quarterly. Contact testing was associated with significantly lower risks of all-cause exit (HR 0.40, 95% CI 0.36–0.44), mortality (HR 0.42, 95% CI 0.31–0.56), and LTFU (HR 0.37, 95% CI 0.32–0.42) in the study population; and those patients receiving their care in model facilities had significantly lower risks of all-cause exit (HR 0.86, 95% CI 0.81–0.91) and LTFU (HR 0.78, 95% CI 0.73–0.83) than those accessing ART in standard support private for-profit facilities.
Table 3
Associations between patient characteristics and all-cause exit, mortality and LTFU

| Hazard ratios (95% CI) | All-cause exit | Mortality | LTFU |
|------------------------|----------------|-----------|------|
| **Sex**                |                |           |      |
| Female                 | 1.0            | 1.0       | 1.0  |
| Male                   | 1.10 (1.04, 1.17) | 1.47 (1.25, 1.73) | 1.08 (1.00, 1.16) |
| **State**              |                |           |      |
| Benue                  | 1.0            | 1.0       | 1.0  |
| FCT                    | 2.61 (1.87, 3.65) | 0.99 (0.48, 2.01) | 5.22 (2.96, 9.22) |
| Nasarawa               | 1.97 (1.41, 2.75) | 0.94 (0.45, 1.91) | 3.66 (2.08, 6.46) |
| **Pregnancy status**   |                |           |      |
| Not pregnant           | 1.0            | 1.0       | 1.0  |
| Pregnant               | 1.09 (0.92, 1.30) | 0.94 (0.48, 2.01) | 1.08 (0.87, 1.33) |
| Breastfeeding          | 0.64 (0.50, 0.81) | 0.32 (0.10, 1.01) | 0.62 (0.46, 0.83) |
| **Age at ART start**† |                |           |      |
| 1st quartile           | 1.0            | 1.0       | 1.0  |
| 2nd quartile           | 0.98 (0.91, 1.06) | 0.69 (0.57, 0.84) | 1.07 (0.97, 1.18) |
| 3rd quartile           | 0.10 (0.92, 1.08) | 0.62 (0.50, 0.77) | 1.12 (1.01, 1.24) |
| 4th quartile           | 1.16 (1.07, 1.26) | 0.54 (0.42, 0.68) | 1.38 (1.25, 1.53) |
| **ARV refill duration**|                |           |      |
| 3 months               | 1.0            | 1.0       | 1.0  |
| 2 months               | 1.13 (1.02, 1.24) | 1.40 (0.99, 1.98) | 1.03 (0.91, 1.17) |
| 1 month                | 2.21 (2.01, 2.43) | 3.34 (2.40, 4.62) | 2.21 (1.97, 2.49) |
| **Contact tested**     |                |           |      |
| No                     | 1.0            | 1.0       | 1.0  |
| Yes                    | 0.40 (0.36, 0.44) | 0.42 (0.31, 0.56) | 0.37 (0.32, 0.42) |
| **Facility support model** |         |           |      |
| Standard               | 1.0            | 1.0       | 1.0  |
| Model                  | 0.86 (0.81, 0.91) | 1.12 (0.96, 1.31) | 0.78 (0.73, 0.83) |

† 1st quartile ≥ 41 years; 2nd quartile 33–40 years; 3rd quartile 28–32 years; 4th quartile 18–27 years
LTFU – Lost to follow up

Regimen switch to 2nd line

The results of multivariate logistic regression modeling of predictors of regimen switch to 2nd line are presented in Table 4. Patients were significantly more likely to switch if they received care at model facilities (OR 2.16, 95% CI 1.55–3.03); were started on AZT-based regimens versus TDF-based regimens (OR 2.00, 95% CI 1.40–2.85); or had a baseline CD4+ cell count in the bottom quartile versus top quartile (OR 2.40, 95% CI 1.47–3.90). Also, as shown in Table 4, odds of regimen switch increased progressively as time on ART increased up till 3–4 years. Odds of switch was not statistically different between those patients treated for 4 years or more when compared to those treated for less than one year.
Table 4
Predictors of ART regimen switch to second line

| Characteristics                  | Odds Ratio (95% CI) |
|----------------------------------|---------------------|
| **Facility support type**        |                     |
| Standard                         | 1.0                 |
| Model                            | 2.16 (1.55, 3.03)   |
| **ART regimen at start**         |                     |
| TDF based                        | 1.0                 |
| AZT based                        | 2.00 (1.40, 2.85)   |
| Other                            | 4.70 (0.58, 38.01)  |
| **Baseline CD4 (cells/microlitre)**† |                   |
| Top quartile                     | 1.0                 |
| 2nd quartile                     | 1.77 (1.04, 2.99)   |
| 3rd quartile                     | 1.21 (0.69, 2.11)   |
| 4th quartile                     | 2.40 (1.47, 3.90)   |
| **Duration on ART**              |                     |
| 0–1 year                         | 1.0                 |
| 1–2 years                        | 3.27 (0.70, 15.21)  |
| 2–3 years                        | 6.86 (1.61, 29.27)  |
| 3–4 years                        | 10.98 (2.62, 45.98) |
| 4+ years                         | 3.81 (0.93, 15.60)  |

† Top quartile 498–4286; 2nd quartile 337–497; 3rd quartile 195–336; 4th quartile 1–194

Virologic outcomes

Overall viral suppression rate on the program was 75.6%. Subjects in Benue had a significantly higher suppression rate of 80.6%, compared to FCT’s 74.4% and Nasarawa’s 73.9% (chi squared test of equal proportions p-value < .0001). Results of univariate and multivariate logistic regressions to determine predictors of viral suppression are shown in Table 5. In the multivariate model, males were less likely to be viral suppressed compared to females (OR 0.84, 95% CI 0.72–0.98), as were patients in FCT (OR 0.40, 95% CI 0.23–0.69) and Nasarawa (OR 0.40, 95% CI 0.23–0.69) compared to those in Benue state. Patients whose starting regimen was AZT-based were less likely to be viral suppressed compared to those started on TDF-based regimen (OR 0.72, 95% CI 0.61–0.86). As shown in Table 5, decreasing age at ART start was associated with progressively worse viral outcomes, with patients in the bottom age quartile having 29% decreased odds (OR 0.71, 95% CI 0.57–0.88) compared to those in the highest age quartile. Viral outcomes showed significant positive trends over time (ART enrolment year) as well as with increased duration on ART (Fig. 1). Subjects in the lowest quartile of baseline CD4+ had significantly lower odds (OR 0.69, 95% CI 0.57–0.83) of viral suppression compared to those in the highest quartile. Contact testing was associated with increased odds of viral suppression (OR 1.19, 95% CI 1.00-1.41), as was receiving care in model facilities (OR 1.30, 95% CI 1.13–1.50).

Figure 1. Trends in viral suppression on the private for-profit HIV program
### Table 5
Predictors of viral suppression in the study population

| Variable                  | Multivariate OR (95% CI) | Variable                  | Multivariate OR (95% CI) |
|---------------------------|--------------------------|---------------------------|--------------------------|
| Sex                       |                          | Facility support type     |                          |
| Female                    | 1.0                      | Standard                  | 1.0                      |
| Male                      | 0.84 (0.72, 0.98)        | Model                     | 1.30 (1.13, 1.50)        |
| State                     |                          | ARV refill duration       |                          |
| Benue                     | 1.0                      | 1 month                   | 1.0                      |
| FCT                       | 0.40 (0.23, 0.69)        | 2 months                  | 1.18 (1.02, 1.36)        |
| Nasarawa                  | 0.40 (0.23, 0.69)        | 3+ months                 | 1.94 (1.54, 2.43)        |
| Age at ART start\*        |                          | Baseline CD4‡             |                          |
| 1st quartile              | 1.0                      | Top quartile              | 1.0                      |
| 2nd quartile              | 0.81 (0.67, 1.00)        | 2nd quartile              | 1.07 (0.87, 1.30)        |
| 3rd quartile              | 0.79 (0.64, 0.98)        | 3rd quartile              | 1.03 (0.85, 1.25)        |
| 4th quartile              | 0.71 (0.57, 0.88)        | 4th quartile              | 0.69 (0.57, 0.83)        |
| ART enrollment year       |                          | ART regimen at start      |                          |
| 2013                      | 1.0                      | TDF based                 | 1.0                      |
| 2014                      | 1.14 (0.90, 1.44)        | AZT based                 | 0.72 (0.61, 0.86)        |
| 2015                      | 1.39 (1.06, 1.83)        | Other                     | 0.88 (0.31, 2.50)        |
| 2016                      | 1.64 (1.22, 2.22)        | Contact tested            |                          |
| 2017                      | 2.16 (1.51, 3.09)        | No                        | 1.0                      |
| 2018                      | 2.15 (1.40, 3.32)        | Yes                       | 1.19 (1.00, 1.41)        |
| Duration on ART           |                          |                           |                          |
| 0–1 year                  | 1.0                      |                           |                          |
| 1–2 years                 | 1.33 (1.02, 1.74)        |                           |                          |
| 2–3 years                 | 1.68 (1.28, 2.19)        |                           |                          |
| 3–4 years                 | 1.70 (1.27, 2.26)        |                           |                          |
| 4+ years                  | 2.27 (1.62, 3.19)        |                           |                          |

† 1st quartile ≥ 41 years; 2nd quartile 33–40 years; 3rd quartile 28–32 years; 4th quartile 18–27 years.
‡ Top quartile 498–4286; 2nd quartile 337–497; 3rd quartile 195–336; 4th quartile 1–194.

### Discussion

Few reports on patient level HIV treatment outcomes from Nigeria have been published, and there is no large-scale outcomes data from private for-profit health facilities. The potential to improve equity and access to health services in low and middle income countries (LMICs) through better private sector engagement is widely recognized in the literature, yet very little empirical information on their effectiveness and quality of service exists [19, 28–35]. This study provides the first private sector data on patient outcomes in a large-
scale HIV treatment program in Nigeria. Benue, Nasarawa and FCT are all in the north-central zone of the country, with significant HIV burdens – 5.3%, 2.0% and 1.6% respectively, compared to a national average of 1.7% [1].

Population estimates for viral suppression among PLHAs in Nigeria vary widely between geo-political zones, ranging from 33.7% in the south-south zone to 65.7% in the north-central [1]. We found an overall viral suppression rate of 75.6% in our study, strengthening the case for expanding the role of private for-profit facilities in HIV care and treatment. Although the viral suppression rate compares favorably with other available data, it falls short of the last 90 of the UNAIDS 95-95-95 targets, pointing to the need to intensify programmatic support and capacity building for these facilities to enhance their quality of care and patient outcomes. This study found better retention in care, lower mortality and higher viral suppression rates in Benue, likely attributable to a longer history of large-scale HIV care and treatment services in the state, as it initially was the target of much programming support, being the first epicenter of Nigeria's HIV epidemic.

Females had better outcomes, including retention in care and viral suppression, which is in keeping with other studies from Nigeria and elsewhere [36–39]. Better health seeking behaviour of women and earlier detection through Prevention of Mother To Child Transmission (PMTCT) interventions may contribute to the observed better outcomes. Low baseline CD4+ counts, use of AZT-based regimens and shorter duration on ART were associated with worse virologic outcomes in this study, consistent with findings of other researchers in Africa and elsewhere[40–47].

Despite the potential that private for-profit health facilities hold, engaging them in public and social services like HIV prevention, care and treatment services is fraught with challenges [29–31, 33, 35]. Private providers are poorly regulated with unclear standards of care that often translates into variable quality of care [29]. In many countries, effective engagement, oversight and regulation of the various private health-care providers may be constrained by imperfect strategic intelligence, limited financial influence and weak institutional capacity [31]. Private facilities are generally small in size, which, coupled with the financial burden associated with private healthcare, results in fewer patients per facility, making program support less efficient [30]. In addition, the core business model of for-profit by the private sector may limit transparency in operations and impose user fees which often makes it difficult for donors to reconcile their goals of minimizing out of pocket expenses [29, 35].

Nonetheless, our study showed that intensified technical support for these facilities (model facility support) yielded significant improvements in quality of care and patient outcomes. Furthermore, performance improved with experience, and outcomes have continued on an upward trajectory (supplemental material). The scale, reach and acceptability of private health facilities make them especially critical to achieving UNAIDS 95-95-95 by 2030 targets.

This study was limited by the non-availability of some data for analysis. Trends in repeat viral load and CD4 + testing records could be informative in understanding determinants of disease progression in the study population but repeat test measures were unavailable for analysis. Also, because viral load testing was not universally accessible during the earlier years of program implementation, testing was prioritized for patients in whom it was specifically indicated, such as those with signs of clinical failure or evidence of poor adherence. This may have resulted in an under-estimate of viral suppression rates and may affect the overall generalizability of our findings.

**Conclusion**

Private for-profit facilities are a major provider of HIV and other health services in Nigeria and other LMICs. Our study shows that despite limited support, patient outcomes are comparable with what obtains in public sector programs. With appropriate technical support and engagement, private for-profit health facilities can help accelerate the achievement of UNAIDS 95-95-95 target by 2030.

**Abbreviations**

NAIIS: Nigerian National AIDS Indicator and Impact Survey; PHIA: Population-based Impact Assessment; PLHIV: People Living with HIV; ART: Antiretroviral Treatment; SCIDaR: Solina Center for International Development and Research; IHVN: Institute of Human Virology, Nigeria; FCT: Federal Capital Territory; PEPFAR: President's Emergency Plan for AIDS Relief; RADET: Retention and Audit Determination Tool; LTFU: Loss To Follow Up.

**Declarations**
Ethics approval and consent to participate

No patient identifiers were extracted from the RADET database for this analysis. This study was reviewed and approved by Nigeria's National Health Research Ethics Committee (NHREC).

Consent for publication

Not Applicable

Availability of data and materials

The datasets generated and analyzed for this study are not publicly available due to ethical reasons, but can be accessed from the corresponding author upon reasonable request.

Competing interests

The authors have no competing interest to disclose.

Funding

The private for-profit HIV care and treatment program on which the study was carried out was funded through a sub-grant from the Institute of Human Virology, Nigeria (IHVN)'s Action to Control HIV Epidemic through Evidence (ACHIEVE) grant number 1U2G GH002099-03 from US Centers for Disease Control and Prevention.

Authors' contributions

MA conceptualized the study, MA and ZY analyzed the data and prepared initial draft and revisions of manuscript and results tables. AS, EE, CM and PD reviewed the manuscript and made critical inputs into its finalization. All authors approved the final manuscript for publication.

Acknowledgements

Not Applicable

References

[1] Survey I. Naïis National Summary Sheet Preliminary Findings Findings By By Sex and and Age Age. 2019; 1–5.
[2] Nigeria_2004_Enaids.Pdf.
[3] NACA. NATIONAL HIV/AIDS PREVENTION PLAN 2014-2015.
[4] Dalhatu I, Onotu D, Odafe S, et al. Outcomes of Nigeria’s HIV/AIDS treatment program for patients initiated on antiretroviral treatment between 2004-2012. *PLoS One* 2016; 11: 1–25.
[5] Pustil R. Global AIDS. *Aids* 2016; 17 Suppl 4: S3-11.
[6] PEPFAR. TANZANIA Country Operational Plan (COP) 2017 Strategic Direction Summary. 2017; 80.
[7] Anude CJ. The HACART study predictors and prediction modeling of loss to follow-up, immuno-virologic outcomes and sub-optimal drug adherence among adults on antiretroviral therapy in Nigeria. Diss Abstr Int, http://ishtmsfx.hosted.exlibrisgroup.com/lshtm?sid=OVID:psycdb&id=pmid:&id=doi:&issn=0419-4217&isbn=9781124760315&volume=72&issue=10-B&page=5845&pages=5845&date=2012&title=Dissertation+Abstracts+International:+Section+B:+The+Sciences+and+Engineering&atitle (2012).
[8] Sharma A, Chilliade P, Michael Reyes E, et al. Building sustainable organizational capacity to deliver HIV programs in resource-constrained settings: stakeholder perspectives. *Glob Health Action* 2013; 6: 22571.
[9] Isa ES, Daniyam CA, Iroezindu M. A decade of Anti-Retroviral Therapy in Nigeria: Efficacy of First Line Regimens in Treatment-Naive HIV / AIDS Patients. 2011; 11: 1–4.

[10] Matsubayashi T, Manabe YC, Etonu A, et al. The effects of an HIV project on HIV and non-HIV services at local government clinics in urban Kampala. BMC Int Health Hum Rights 2011; 11 Suppl 1: S9.

[11] Ministerio de Salud Pública del Ecuador. Plan Estratégico Multisectorial para la respuesta al VIH 2018-2022. Program HIV/AIDS 2018; 1–60.

[12] Project UA. Nigeria’s Mixed Epidemic.

[13] Only IU. Nigeria’s COP 2019 Vision.

[14] Fox AM. The social determinants of HIV serostatus in sub-Saharan Africa: An inverse relationship between poverty and HIV? Public Health Rep 2010; 125: 16–24.

[15] Dalhatu I, Onotu D, Odafe S, et al. Outcomes of Nigeria’s HIV/AIDS treatment program for patients initiated on antiretroviral treatment between 2004-2012. PLoS One 2016; 11: e0165528.

[16] Sulzbach S, De S, Wang W. The private sector role in HIV/AIDS in the context of an expanded global response: Expenditure trends in five sub-Saharan African countries. Health Policy Plan 2011; 26: 72–84.

[17] Davies P. The Role of the Private Sector in the Context of Aid Effectiveness. Consult Find Doc 2011; 1–8.

[18] Okonkwo P, Sagay AS, Agaba PA, et al. Treatment Outcomes in a Decentralized Antiretroviral Therapy Program: A Comparison of Two Levels of Care in North Central Nigeria. AIDS Res Treat 2014; 2014: 1–10.

[19] Mills A, Brughia R, Hanson K, et al. What can be done about the private health sector in low-income countries? Bull World Health Organ 2002; 80: 325–330.

[20] Matson JL. Social behavior and skills in children. Soc Behav Ski Child 2009; 1–333.

[21] Joint United Nations Program on HIV/AIDS. to help end the AIDS epidemic. United Nations.

[22] Sidibé M, Loures L, Samb B. The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc 2016; 19: 21133.

[23] Barnes J, Chandani T, Feeley R. NIGERIA PRIVATE SECTOR HEALTH ASSESSMENT-Private sector partnership One project. Development.

[24] NDHS. Nigeria Demographic and Health Survey 2008, National Population Commission federal Republic Of Nigeria Abuja, Nigeria ICF Macro Calverton, Maryland , USA.

[25] PharmAccess Foundation. Nigerian Health Sector Market Study Report. pharmAccess Found 2014; 1–52.

[26] Support ST. How do I cite the Stata software, documentation, and FAQs? Citing the Stata software Citing the Stata documentation Citing Stata FAQs. 2018; 2017–2019.

[27] UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. October, 2014. http://www unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf (accessed May 21, 2017).

[28] Sulzbach S, De S, Wang W. The private sector role in HIV/AIDS in the context of an expanded global response: Expenditure trends in five sub-Saharan African countries. Health Policy Plan 2011; 26: 72–84.

[29] Ezechi OC, Oladele DA, Dureke F, et al. Private Health Sector Engagement in the National HIV Response in Nigeria: Findings from a Nationally Representative Sample of Stakeholders. Niger J Heal Sci 2014; 14: 23–28.
[30] Ejughemre UJ. Accelerated reforms in healthcare financing: the need to scale up private sector participation in Nigeria. *Int J Heal Policy Manag* 2014; 2: 13–19.

[31] WHO. Strengthening the capacity of governments to constructively engage the private sector in providing essential health-care services Report by the Secretariat. *Sixty-third World Heal Assem* 2010; 25–27.

[32] Patouillard E, Goodman CA, Hanson KG, et al. Can working with the private for-profit sector improve utilization of quality health services by the poor? A systematic review of the literature. *Int J Equity Health* 2007; 6: 1–11.

[33] Loevinsohn B, Harding A. Buying results? Contracting for health service delivery in developing countries. *Lancet* 2005; 366: 676–681.

[34] Forsberg BC, Montagu D. Further advances in knowledge on the role of the private sector in health systems. *Health Policy Plan* 2014; 29: 1–3.

[35] Davies P. The Role of the Private Sector in the Context of Aid Effectiveness. *Consult Find Doc* 2011; 1–8.

[36] Aliyu A, Adelekan B, Andrew N, et al. Predictors of loss to follow-up in art experienced patients in Nigeria: A 13 year review (2004-2017). *AIDS Res Ther* 2019; 16: 1–9.

[37] Lay P, An S, Soeung S, et al. Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes. *PLoS One* 2017; 12: e0185348.

[38] Bekolo CE, Webster J, Batenganya M, et al. Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon. *BMC Res Notes* 2013; 6: 512.

[39] Mosha F, Muchunguzi V, Matee M, et al. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. *BMC Public Health* 2013; 13: 38.

[40] Amoroso A, Etienne-Mesubi M, Edozien A, et al. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. *J Acquir Immune Defic Syndr* 2012; 60: 314–320.

[41] Louis FJ, Buteau J, François K, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. *PLoS One* 2018; 13: e0192077.

[42] Wolff M, Shepherd BE, Cortés C, et al. Clinical and Virologic Outcomes after Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network. *J Acquir Immune Defic Syndr* 2016; 71: 102–110.

[43] Costiniuk CT, Sigal A, Jenabian M-A, et al. Short Communication: Lower Baseline CD4 Count Is Associated with a Greater Propensity Toward Virological Failure in a Cohort of South African HIV Patients. *AIDS Res Hum Retroviruses* 2014; 30: 531–534.

[44] Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infect Dis* 2015; 15: 517.

[45] Huang P, Tan J, Ma W, et al. Outcomes of antiretroviral treatment in HIV-infected adults: A dynamic and observational cohort study in Shenzhen, China, 2003-2014. *BMJ Open* 2015; 5: e007508.

[46] Welfare F. *National Guidelines for HIV Testing*, http://www.naco.gov.in/upload/2016 Data/LS/National Guidelines for HIV Testing_21Apr2016.pdf (2014).

[47] Ayele T, Jarso H, Mamo G. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: A two years retrospective cohort study. *AIDS Res Ther* 2017; 14: 1–9.

**Supplemental Material**

Supplemental Material is not available with this version of the manuscript.
Figures

Adjusted OR by year of enrolment on ART

Adjusted OR by time on ART (Years)

*R² = 0.9526

*R² = 0.9429

†Coefficient of determination for fitted linear trendline

Figure 1

Trends in viral suppression on the private for-profit HIV program